Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I.

Ann Hematol. 2019 Aug 7. doi: 10.1007/s00277-019-03767-y. [Epub ahead of print]

PMID:
31392461
2.

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

Dragani M, Rege-Cambrin G, Ferrero D, Abruzzese E, Pregno P, Elena C, Cedrone M, Santoro M, Andreani G, Saglio G, Fava C.

Leuk Lymphoma. 2019 Jun 4:1-3. doi: 10.1080/10428194.2019.1622103. [Epub ahead of print] No abstract available.

PMID:
31161827
3.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

4.

Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.

Di Veroli A, Buccisano F, Andriani A, Montanaro M, Latagliata R, Santoro C, Breccia M, Spirito F, Cedrone M, Anaclerico B, Leonetti Crescenzi S, Porrini R, De Muro M, Avvisati G, Tafuri A, Cimino G, Spadea A.

Leuk Res. 2018 Jun;69:18-23. doi: 10.1016/j.leukres.2018.03.016. Epub 2018 Mar 31. No abstract available.

PMID:
29625320
5.

High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.

Latagliata R, Montanaro M, Cedrone M, Di Veroli A, Spirito F, Santoro C, Leonetti Crescenzi S, Porrini R, Di Giandomenico J, Villivà N, Spadea A, Rago A, De Gregoris C, Romano A, Anaclerico B, De Muro M, Felici S, Breccia M, Montefusco E, Bagnato A, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A; Gruppo Laziale, SMPC Ph1.

Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21.

PMID:
28662484
6.

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG.

Cancer Med. 2017 Jun;6(6):1233-1239. doi: 10.1002/cam4.1081. Epub 2017 May 23.

7.

Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.

Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villivà N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R.

Ann Hematol. 2017 Mar;96(3):387-391. doi: 10.1007/s00277-016-2884-7. Epub 2016 Nov 26.

PMID:
27889820
8.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

9.

Dasatinib first-line: Multicentric Italian experience outside clinical trials.

Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G.

Leuk Res. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. Epub 2015 Nov 17.

PMID:
26643920
10.

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.

Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G.

Leuk Res. 2015 Oct;39(10):1055-9. doi: 10.1016/j.leukres.2015.07.004. Epub 2015 Jul 14.

PMID:
26282944
11.

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.

Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G.

Eur J Haematol. 2016 Jun;96(6):643-9. doi: 10.1111/ejh.12674. Epub 2015 Sep 18.

PMID:
26277477
12.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Haematologica. 2015 Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. Epub 2015 Jun 25.

13.

Altered fetal skeletal muscle nutrient metabolism following an adverse in utero environment and the modulation of later life insulin sensitivity.

Dunlop K, Cedrone M, Staples JF, Regnault TR.

Nutrients. 2015 Feb 12;7(2):1202-16. doi: 10.3390/nu7021202. Review.

14.

Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis.

Rago A, Latagliata R, Montanaro M, Montefusco E, Andriani A, Crescenzi SL, Mecarocci S, Spirito F, Spadea A, Recine U, Cicconi L, Avvisati G, Cedrone M, Breccia M, Porrini R, Villivà N, De Gregoris C, Alimena G, D'Arcangelo E, Guglielmelli P, Lo-Coco F, Vannucchi A, Cimino G.

Leuk Res. 2015 Mar;39(3):314-7. doi: 10.1016/j.leukres.2015.01.001. Epub 2015 Jan 12.

PMID:
25636356
15.

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.

Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G.

Leuk Res. 2014 Oct;38(10):1173-6. doi: 10.1016/j.leukres.2014.06.020. Epub 2014 Jul 7.

PMID:
25047978
16.

Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients.

Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, Spirito F, Porrini R, De Muro M, Leonetti SC, Villivà N, De Gregoris C, Breccia M, Montefusco E, Santoro C, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A.

Am J Hematol. 2014 May;89(5):542-6. doi: 10.1002/ajh.23685. Epub 2014 Feb 21.

17.

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G.

Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.

PMID:
23681399
18.

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.

Latagliata R, Spadea A, Cedrone M, Di Giandomenico J, De Muro M, Villivà N, Breccia M, Anaclerico B, Porrini R, Spirito F, Rago A, Avvisati G, Alimena G, Montanaro M, Andriani A; Gruppo Laziale SMPC Ph1 neg.

Cancer. 2012 Jan 15;118(2):404-9. doi: 10.1002/cncr.26194. Epub 2011 Jun 20.

19.

A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias.

Gruszka AM, Lavorgna S, Consalvo MI, Ottone T, Martinelli C, Cinquanta M, Ossolengo G, Pruneri G, Buccisano F, Divona M, Cedrone M, Ammatuna E, Venditti A, de Marco A, Lo-Coco F, Pelicci PG.

Blood. 2010 Sep 23;116(12):2096-102. doi: 10.1182/blood-2010-01-266908. Epub 2010 Jun 10.

20.

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party.

Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12.

21.

Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.

Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, Martino B, Scalzulli PR, Latagliata R, Palmieri F, Usala E, Valente D, Valvano MR, Cedrone M, Comitini G, Martinelli V, Cascavilla N, Gugliotta L.

Am J Hematol. 2009 Oct;84(10):636-40. doi: 10.1002/ajh.21504.

22.

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.

Riccioni R, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, Ottone T, Foà R, Testa U.

Br J Haematol. 2009 Feb;144(3):376-87. doi: 10.1111/j.1365-2141.2008.07491.x. Epub 2008 Nov 13.

PMID:
19036083
23.

M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.

Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, Lo-Coco F, Foà R, Peschle C, Testa U.

Br J Haematol. 2007 Oct;139(2):194-205.

PMID:
17897295
24.

Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts.

Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foà R, Peschle C, Testa U.

Stem Cells. 2007 Aug;25(8):1862-71. Epub 2007 Apr 19.

25.

Podocalyxin is expressed in normal and leukemic monocytes.

Riccioni R, Calzolari A, Biffoni M, Senese M, Riti V, Petrucci E, Pasquini L, Cedrone M, Lo-Coco F, Diverio D, Foà R, Peschle C, Testa U.

Blood Cells Mol Dis. 2006 Nov-Dec;37(3):218-25. Epub 2006 Oct 23.

PMID:
17059890
26.

TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.

Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foà R, Lo Coco F, Peschle C, Testa U.

Haematologica. 2005 May;90(5):612-24.

27.

Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients.

Mancini M, Cedrone M, Diverio D, Emanuel B, Stul M, Vranckx H, Brama M, De Cuia MR, Nanni M, Fazi F, Mecucci C, Alimena G, Hagemeijer A.

Leukemia. 2000 Mar;14(3):364-8.

PMID:
10720127
28.

Management of infective complications in patients with advanced hematologic malignancies in home care.

Girmenia C, Moleti ML, Cartoni C, Cedrone M, De Gregoris C, De Sanctis V, Giovannini M, Latagliata R, Niscola P, Romani C, Rondinelli MB, Tosti S, Mandelli F.

Leukemia. 1997 Nov;11(11):1807-12.

PMID:
9369410
29.

Clinical and cytologic characteristics of blastic phase in Ph-positive chronic myeloid leukemia treated with alpha-interferon.

Alimena G, Lazzarino M, Morra E, Mancini M, Cedrone M, Montefusco E, Merante S, Meloni G, Bernasconi P, Rondinelli MB, Bernasconi C, Mandelli F.

Leukemia. 1996 Apr;10(4):615-8.

PMID:
8618436
30.

Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission.

Mancini M, Nanni M, Cedrone M, Diverio D, Avvisati G, Riccioni R, De Cuia MR, Fenu S, Alimena G.

Br J Haematol. 1995 Dec;91(4):878-84.

PMID:
8547133
31.

Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.

Todisco E, Testi AM, Avvisati G, Moleti ML, Cedrone M, Cimino G, Mancini F, Amadori S, Mandelli F.

Leukemia. 1995 Sep;9(9):1583-5.

PMID:
7658728
32.

Acute leukemia presenting a variant Ph chromosome with p190 expression, dup 3q and -7, developed after malignant lymphoma treated with alkylating agents and topoisomerase II inhibitors.

Alimena G, Cedrone M, Nanni M, De Cuia MR, Lo Coco F, De Sanctis V, Cimino G, Mancini M.

Leukemia. 1995 Sep;9(9):1483-6.

PMID:
7658716
33.

Application of fluorescence in situ hybridization in defining a complex t(9;21;22) Ph formation.

Mancini M, Nanni M, Cedrone M, De Cuia MR, Rondinelli MB, Malagnino F, Alimena G.

Haematologica. 1994 Nov-Dec;79(6):536-9.

34.

Myelodysplastic syndromes in childhood: description of seven cases.

Vitale A, Testi AM, Moleti ML, Vignetti M, Arcese W, Fenu S, Cedrone M, De Felice L, Amadori S, Mandelli F.

Ann Hematol. 1994 May;68(5):241-5.

PMID:
8018765
35.

Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: experience of treatments during a ten-year period.

Annino L, Ferrari A, Cedrone M, Giona F, Lo Coco F, Meloni G, Arcese W, Mandelli F.

Leukemia. 1994 Apr;8(4):664-7.

PMID:
8152262
36.

Trisomy 14 in hematologic diseases. Another non-random abnormality within myeloid proliferative disorders.

Mancini M, Cedrone M, Nanni M, Rondinelli MB, Petti MC, De Cuia MR, Alimena G.

Cancer Genet Cytogenet. 1993 Mar;66(1):39-42. Review.

PMID:
8467473
37.

Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.

Alimena G, Meloni G, de Cuia MR, Rondinelli MB, Lo Coco F, Montefusco E, Mancini M, Pinto R, Nanni M, Cedrone M, et al.

Leuk Lymphoma. 1993;11 Suppl 1:281-91.

PMID:
7902746
38.

Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome.

Montefusco E, Alimena G, Lo Coco F, De Cuia MR, Wang YZ, Aloe Spiriti MA, Mancini F, Cedrone M, Mancini M, Mandelli F.

Ann Hematol. 1992 Jul;65(1):17-21.

PMID:
1643155
39.

Unbalanced 6p translocation as primary karyotypic anomaly in secondary acute nonlymphocytic leukemia.

Mancini M, Mecucci C, Cedrone M, Rondinelli MB, Aloe-Spiriti MA, Alimena G.

Cancer Genet Cytogenet. 1992 May;60(1):93-5.

PMID:
1591714
40.

Reciprocal translocation involving 3q21 in an unusual myeloproliferative disorder with myelodysplastic features and prominent dysmegakaryopoiesis.

Cedrone M, Mecucci C, Burgio VL, Diverio D, Petti MC, Alimena G.

Cancer Genet Cytogenet. 1991 Jan;51(1):73-8. Review.

PMID:
1984850
41.

Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.

Lo Coco F, Mandelli F, Diverio D, Alimena G, De Fabritiis P, Meloni G, Cedrone M, Frontani M, Guerrasio A, Saglio G.

Bone Marrow Transplant. 1990 Oct;6(4):253-8.

PMID:
2085700
42.

Cytogenetic follow-up after allogeneic bone-marrow transplantation for Ph1-positive chronic myelogenous leukemia.

Alimena G, De Cuia MR, Mecucci C, Arcese W, Mauro F, Screnci M, Mancini M, Cedrone M, Nanni M, Montefusco E, et al.

Bone Marrow Transplant. 1990 Feb;5(2):119-27.

PMID:
2310876
43.

Prolonged effect of alpha-interferon after discontinuance of treatment in chronic myelogenous leukemia patients.

Alimena G, Montefusco E, Mancini M, De Fabritiis P, Cedrone M, Sandrelli A, Mandelli F.

Eur J Haematol. 1989 Aug;43(2):108-11.

PMID:
2792317

Supplemental Content

Loading ...
Support Center